Neutralizing antibody P2-1B1 neutralizing a broad spectrum of SARS-CoV-2 and applications thereof

Abstract

The application discloses a neutralizing antibody P2-1B1 for neutralizing SARS-CoV-2 in a broad spectrum and application thereof. The application provides an IgG antibody, named P2-1B1 antibody, which is composed of a light chain and a heavy chain; CDR1, CDR2 and CDR3 in a heavy chain variable region in the heavy chain are sequentially shown in the 26th-33rd position, the 51st-58th position and the 97th-114th position of SEQ ID NO:1; CDR1, CDR2 and CDR3 in a light chain variable region in the light chain are sequentially shown in the 27th-38th position, the 56th-58th position and the 95th-103th position of SEQ ID NO:4. The P2-1B1 antibody provided by the application has the effect of neutralizing SARS-CoV-2 in a broad spectrum, and has strong neutralization capacity to wild-type novel coronavirus and natural mutant strains. The application has great application value for prevention and control of the novel coronavirus, and will have far-reaching social significance.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of biotechnology, and relates to a neutralizing antibody P2-1B1 for neutralizing SARS-CoV-2 in a broad spectrum and application thereof. BACKGROUND

[0002] The new crown infection is caused by the novel coronavirus infection, and the main symptoms are low fever, fatigue and dry cough, and a small number of patients also have symptoms such as nasal congestion, runny nose, diarrhea and upper respiratory tract and digestive tract. Severe patients will develop into acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction and multiple organ failure. The novel coronavirus (SARS-CoV-2) belongs to the beta genus coronavirus.

[0003] SARS-CoV-2 produces many mutations in the process of transmission, enhances its transmission and immune escape, and the current main epidemic natural mutant strains include the Alpha strain found in the United Kingdom, the Beta strain found in South Africa, the Gamma strain found in Brazil and the like. The vaccine immunity against the novel coronavirus has also been affected, and the neutralization activity of the inactivated vaccine immune serum against the South African mutant strain is reduced by half, the neutralization activity of the mRNA vaccine immune serum against the South African mutant strain is reduced by about 10 times, and many monoclonal antibodies also weaken or lose the neutralization activity against the mutant strain.

[0004] Monoclonal antibodies can be mass-produced industrially, and the high affinity and high specificity of the monoclonal antibodies in combination with antigens greatly reduce the adverse reactions in clinical application. At the same time, the antibody molecules can be modified to increase their antiviral efficacy. Antibodies are very promising means in the treatment of infectious diseases due to their specificity and flexibility of use. At present, it is urgent to cope with the challenge of the natural mutant strain of the novel coronavirus, and to develop a broad-spectrum human monoclonal antibody against the novel coronavirus, which will provide more effective prevention and treatment means for the natural mutant strain of the novel coronavirus infection. SUMMARY

[0005] The purpose of the present application is to provide a neutralizing antibody P2-1B1 for neutralizing SARS-CoV-2 in a broad spectrum and application thereof.

[0006] The present application provides an IgG antibody, named P2-1B1 antibody, which is composed of a light chain and a heavy chain; the CDR1, CDR2 and CDR3 in the heavy chain variable region in the heavy chain are sequentially shown in SEQ ID NO: 1, 26-33, 51-58, 97-114; the CDR1, CDR2 and CDR3 in the light chain variable region in the light chain are sequentially shown in SEQ ID NO: 4, 27-38, 56-58, 95-103.

[0007] Specifically, the heavy chain variable region is shown in SEQ ID NO: 1.

[0008] Specifically, the light chain variable region is shown in SEQ ID NO: 4.

[0009] Specifically, the heavy chain is the following (a) or (b): (a) the protein shown at positions 20-474 in SEQ ID NO: 2; (b) the protein shown in SEQ ID NO: 2.

[0010] Specifically, the light chain is (c) or (d) as follows: (c) the protein shown at positions 20-239 in SEQ ID NO: 5; (d) the protein shown in SEQ ID NO: 5.

[0011] The gene encoding the IgG antibody also falls within the scope of protection of the present invention.

[0012] Specifically, the gene encoding the heavy chain is as follows (1) or (2):

[0013] (1) the DNA molecule represented by nucleotides 949-2316 of SEQ ID NO: 3;

[0014] (2) The DNA molecule represented by nucleotides 892-2316 in SEQ ID NO: 3.

[0015] Specifically, the gene encoding the light chain is as follows (3) or (4):

[0016] (3) the DNA molecule represented by nucleotides 1095-1757 of SEQ ID NO: 6;

[0017] (4) The DNA molecule represented by nucleotides 1038-1757 in SEQ ID NO: 6.

[0018] The present invention also protects the use of any of the above-mentioned IgG antibodies in the preparation of drugs for inhibiting the new coronavirus.

[0019] The present invention also protects a drug for inhibiting the new coronavirus, the active ingredient of which is any of the above-mentioned IgG antibodies.

[0020] The present invention also protects the use of any of the above-mentioned IgG antibodies in the preparation of drugs for neutralizing the new coronavirus.

[0021] The present invention also protects a drug for neutralizing the new coronavirus, the active ingredient of which is any of the above-mentioned IgG antibodies.

[0022] The present invention also protects the use of any of the above-mentioned IgG antibodies in the preparation of drugs for preventing and / or treating new coronavirus infections.

[0023] The present application also protects a medicine for preventing and / or treating COVID-19 infection, the active ingredient of which is any of the IgG antibodies described above.

[0024] Any of the COVID-19 infections described above is a novel coronavirus infection.

[0025] Any of the novel coronaviruses described above is a wild-type novel coronavirus or a naturally mutated strain of wild-type novel coronavirus.

[0026] Any of the novel coronaviruses described above is a novel coronavirus D614G mutant strain.

[0027] Any of the novel coronaviruses described above is a wild-type novel coronavirus, a novel coronavirus Alpha strain, a novel coronavirus Beta strain, a novel coronavirus Gamma strain, a novel coronavirus Delta strain, a novel coronavirus Delta plus strain, a novel coronavirus Mu strain, or a novel coronavirus Omicron strain.

[0028] Specifically, the novel coronavirus Omicron strain is a novel coronavirus Omicron BA.1 strain, a novel coronavirus Omicron BA.2.12.1 strain, a novel coronavirus Omicron BA.2.75 strain, a novel coronavirus Omicron BA.3 strain, or a novel coronavirus Omicron BA.4 / 5 strain.

[0029] The present application uses the spike protein of the novel coronavirus as bait to screen antibody-producing memory B cells from the peripheral blood mononuclear cells of infected individuals, and obtains a monoclonal antibody that can specifically bind to the spike protein, named P2-1B1 antibody. The P2-1B1 antibody provided by the present application has a broad-spectrum neutralizing effect on SARS-CoV-2, and has strong neutralizing ability for wild-type novel coronavirus and naturally mutated strains. The present application has great application value for the prevention and control of novel coronavirus, and will have far-reaching social significance. BRIEF DESCRIPTION OF DRAWINGS

[0030] Figure 1 Neutralizing activity of P2-1B1 antibody on novel coronavirus pseudovirus. DETAILED DESCRIPTION

[0031] The present application will be further described in detail below in conjunction with the specific embodiments, and the examples given are only for illustrating the present application, but not for limiting the scope of the present application. The examples provided below can serve as a guide for further improvement by those of ordinary skill in the art, and do not in any way constitute a limitation on the present application.

[0032] The experimental methods in the following examples are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions, unless otherwise specified. The materials, reagents, etc. used in the following examples can be obtained commercially, unless otherwise specified. The quantitative tests in the following examples are all set up in triplicate, and the results are averaged, unless otherwise specified. The 293F cells and 293T cells are both commercially available human embryonic kidney epithelial cells. The pMD18-T vector is a commercially available plasmid vector. The pcDNA3.1(+) vector: Invitrogen, product catalog number V790-20.

[0033] hACE2-hela cells (i.e. “HeLa cell lines stably expressing the ACE2 molecules” in the literature) are described in the following literature: Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., Liao, H., Feng, Y., Li, X., Shi, X., Zhang, Z., Zhang, F., Ding, Q., Zhang, T., Wang, X. & Zhang, L. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity 54, 1611-1621.e1615, doi:10.1016 / j.immuni.2021.06.003 (2021).

[0034] Example 1, Discovery and preparation of P2-1B1 antibody

[0035] I. Discovery of P2-1B1 antibody

[0036] Memory B cells were isolated from the peripheral blood mononuclear cells of a SARS-CoV-2 convalescent patient, and the antibody genes of the memory B cells were amplified to obtain the antibody sequences. Through a large number of comparisons, analyses, preparations and effect verifications, the inventors of the present application discovered a new SARS-CoV-2 IgG antibody with excellent activity, which was named P2-1B1 antibody.

[0037] The amino acid sequence of the heavy chain variable region of the P2-1B1 antibody is shown in SEQ ID NO: 1 (CDR1, CDR2 and CDR3 are located at positions 26-33, 51-58, 97-114, respectively; CDR1, CDR2 and CDR3 are GGTFSSYA, IIPIFGTP, SRTKGDILTGYTDYYFDS, respectively). The amino acid sequence of the full-length heavy chain of the P2-1B1 antibody is shown in SEQ ID NO: 2; in SEQ ID NO: 2, the amino acid residues at positions 1-19 constitute a signal peptide (which guides the protein to be secreted outside the cell), the amino acid residues at positions 20-144 constitute a heavy chain variable region, and the amino acid residues at positions 145-474 constitute a heavy chain constant region.

[0038] The amino acid sequence of the light chain variable region of the P2-1B1 antibody is shown in SEQ ID NO: 4 (CDR1, CDR2 and CDR3 are located at positions 27-38, 56-58, 95-103, respectively; CDR1, CDR2 and CDR3 are QSVLHSSNNKNY, WAS, QQYYSTPIS, respectively). The amino acid sequence of the full-length light chain of the P2-1B1 antibody is shown in SEQ ID NO: 5; in SEQ ID NO: 5, the amino acid residues at positions 1-19 constitute a signal peptide (which guides the protein to be secreted outside the cell), the amino acid residues at positions 20-132 constitute a light chain variable region, and the amino acid residues at positions 133-239 constitute a light chain constant region.

[0039] II. Preparation of the P2-1B1 antibody

[0040] (I) Construction of the recombinant plasmid

[0041] The heavy chain DNA molecule is a double-stranded DNA molecule, as shown in SEQ ID NO: 3. In SEQ ID NO: 3, the nucleotides at positions 1-891 constitute a promoter, the nucleotides at positions 892-2316 encode a full-length heavy chain, and the nucleotides at positions 2317-2462 constitute a terminator. The heavy chain DNA molecule is inserted into a pMD18-T vector to obtain a heavy chain expression vector.

[0042] The light chain DNA molecule is a double-stranded DNA molecule, as shown in SEQ ID NO: 6. In SEQ ID NO: 6, the nucleotides at positions 1-1037 constitute a promoter, the nucleotides at positions 1038-1757 encode a full-length light chain, and the nucleotides at positions 1758-1905 constitute a terminator. The light chain DNA molecule is inserted into a pMD18-T vector to obtain a light chain expression vector.

[0043] (II) Construction of the recombinant cell

[0044] The heavy chain expression vector and the light chain expression vector are co-transfected into 293F cells to obtain a recombinant cell.

[0045] (III) Preparation of the antibody

[0046] 1. The recombinant cells obtained in step (II) were cultured in DMEM medium containing 2% fetal bovine serum for 72 h, then centrifuged at 4°C, 4000 rpm for 30 min, and the supernatant was collected.

[0047] 2. Affinity chromatography

[0048] The specifications of the chromatography column for affinity chromatography: length 3 cm, inner diameter 1 cm;

[0049] The column packing for affinity chromatography: protein A beads (Thermo, product catalog number 10006D);

[0050] Operation steps: ① 300 mL of supernatant obtained in step 1 was loaded onto the affinity chromatography column, and incubated at 4°C for 16 hours; ② The column was washed with 60 ml of binding buffer; ③ The target protein was eluted with 30 mL of elution buffer, and the solution after passing through the column was collected.

[0051] Binding buffer: Take glycine 112.6 g, sodium chloride 175.2 g, dissolve in water and dilute to 1 L with water, adjust pH to 8.0 with sodium hydroxide.

[0052] Elution buffer: Take glycine 7.5 g, dissolve in water and dilute to 500 ml with water, adjust pH to 3.0 with hydrochloric acid.

[0053] 3. The solution after passing through the column obtained in step 2 was concentrated with an ultrafiltration concentration tube and the system was replaced with PBS buffer (pH 7.2, 10 mM) to obtain P2-1B1 antibody solution (antibody concentration about 1 mg / ml).

[0054] Example 2, neutralization test

[0055] I. Preparation of novel coronavirus pseudovirus

[0056] The plasmid expressing the spike protein of the novel coronavirus and the backbone plasmid pNL4-3R-E-luciferase are co-transfected into 293T cells, and after incubation, a novel coronavirus pseudovirus with infectivity but without replication ability can be obtained, and its infectivity is similar to that of the live novel coronavirus virus. The backbone plasmid pNL4-3R-E-luciferase, i.e., the backbone plasmid pNL4-3R-E containing the luciferase, is recorded in the following literature: Wang Q, Liu L, Ren W, Gettie A, Wang H, Liang Q, Shi X, Montefiori DC, Zhou T, Zhang L. Cell Rep. 2019.

[0057] The coding gene of the spike protein of the novel coronavirus is inserted between the BamHII and EcoRI enzyme cutting sites of the pcDNA3.1(+) vector to obtain a plasmid expressing the spike protein of the novel coronavirus. The plasmid expressing the spike protein of the novel coronavirus and the backbone plasmid pNL4-3R-E-luciferase are co-transfected into 293T cells, and incubated at 37°C (DMEM medium containing 10% fetal bovine serum is used), and the cell culture supernatant is collected after 60 hours of transfection, which is the virus liquid containing the novel coronavirus pseudovirus. Virus liquids of pseudoviruses of 12 novel coronavirus strains are prepared respectively. The 12 novel coronavirus strains refer to the novel coronavirus D614G mutant strain, the novel coronavirus Alpha strain, the novel coronavirus Beta strain, the novel coronavirus Gamma strain, the novel coronavirus Delta strain, the novel coronavirus Delta plus strain, the novel coronavirus Mu strain, the novel coronavirus Omicron BA.1 strain, the novel coronavirus Omicron BA.2.12.1 strain, the novel coronavirus Omicron BA.2.75 strain, the novel coronavirus Omicron BA.3 strain, and the novel coronavirus Omicron BA.4 / 5 strain.

[0058] The spike protein of the wild-type novel coronavirus (WT) is shown in SEQ ID NO: 7. The coding gene of the spike protein of the wild-type novel coronavirus is recorded in the full genome of GenBank: MN908947.3 (18-MAR-2020) at positions 21563-25384.

[0059] The spike protein of the novel coronavirus D614G mutant strain has the following mutation relative to the spike protein of the wild strain: D614G. The coding gene of the spike protein of the novel coronavirus D614G mutant strain is shown as SEQ ID NO: 8.

[0060] The spike protein of the novel coronavirus Alpha strain (Pango lineage B.1.1.7) has the following mutations relative to the spike protein of the wild strain: 69-70del (HV), 144del (Y), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H. The coding gene of the spike protein of the novel coronavirus Alpha strain is recorded in GISAID: EPI_ISL_601443.

[0061] The spike protein of the novel coronavirus Beta strain (Pango lineage B.1.351) has the following mutations relative to the spike protein of the wild strain: L18F, D80A, D215G, 242-244del (LLA), S305T, K417N, E484K, N501Y, D614G, A701V. The coding gene of the spike protein of the novel coronavirus Beta strain is recorded in GISAID: EPI_ISL_700450.

[0062] The spike protein of the novel coronavirus Gamma strain (Pango lineage P.1) has the following mutations relative to the spike protein of the wild strain: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F. The coding gene of the spike protein of the novel coronavirus Gamma strain is recorded in GISAID: EPI_ISL_792681.

[0063] The spike protein of the novel coronavirus Delta strain (Pango lineage B.1.617.2) has the following mutations relative to the spike protein of the wild strain: T19R, G142D, 156-157del (EF), R158G, A222V, L452R, T478K, D614G, P681R, D950N. The coding gene of the spike protein of the novel coronavirus Delta strain is recorded in GISAID: EPI_ISL_1534938.

[0064] The spike protein of the SARS-CoV-2 Delta plus variant (Pango lineage AY.x) has the following mutation increased relative to the spike protein of the Delta variant: K417N. The coding gene for the spike protein of the SARS-CoV-2 Delta plus variant is reported at GISAID: EPI_ISL_3019629.

[0065] The spike protein of the SARS-CoV-2 Mu variant (Pango lineage B.1.621) has the following mutations relative to the spike protein of the wild-type: T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H, D950N. The coding gene for the spike protein of the SARS-CoV-2 Mu variant is reported at GISAID: EPI_ISL_3987640.

[0066] The spike protein of the SARS-CoV-2 Omicron BA.1 variant (Pango lineage BA.1) has the following mutations relative to the spike protein of the wild-type: A67V, Δ69-70(HV), T95I, G142D, Δ143-145(VYY), Δ211(N), L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F. The coding gene for the spike protein of the SARS-CoV-2 Omicron BA.1 variant is reported at GISAID: EPI_ISL_6752027.

[0067] The spike protein of the SARS-CoV-2 Omicron BA.2.12.1 strain (Pango lineage BA.2.12.1) has the following mutations relative to the spike protein of the wild-type strain: T19I, 24-26del (LPP), A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The coding gene for the spike protein of the SARS-CoV-2 Omicron BA.2.12.1 strain is reported at GISAID: EPI_ISL_12560123.

[0068] The spike protein of the SARS-CoV-2 Omicron BA.2.75 strain has the following mutations relative to the spike protein of the wild-type strain: T19I, del24-26 (LPP), A27S, G142D, K147E, W152R, F157L, I210V, V213G, G257S, G339H, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The coding gene for the spike protein of the SARS-CoV-2 Omicron BA.2.75 strain is reported at GISAID: EPI_ISL_14393635.

[0069] The spike protein of the novel coronavirus Omicron BA.3 strain (Pango lineage BA.3) has the following mutations relative to the spike protein of the wild type: A67V, del69-70(HV), T95I, G142D, del143-145(VYY), 211del(N), L212I, G339D, S371F, S373P, S375F, D405N, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The coding gene of the spike protein of the novel coronavirus Omicron BA.3 strain is recorded in GISAID: EPI_ISL_7740765.

[0070] The spike protein of the novel coronavirus Omicron BA.4 / 5 strain (Pango lineage BA.4) has the following mutations relative to the spike protein of the wild type: T19I, 24-26del(LPP), A27S, del69-70(HV), G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The coding gene of the spike protein of the novel coronavirus Omicron BA.4 / 5 strain is recorded in EPI_ISL_12559461.

[0071] II. Detection of neutralizing activity of antibodies

[0072] Test virus solution: virus solution of the 12 novel coronavirus strains of pseudovirus prepared in step one.

[0073] 1. Take the P2-1B1 antibody solution prepared in Example 1, dilute it with PBS buffer (pH 7.2, 10 mM) to obtain antibody dilutions of various concentrations.

[0074] 2. Take 96-well cell culture plates, add 100 microliters of antibody dilutions and 50 microliters of test virus solution (the virus concentration in 50 microliters of test virus solution is 1 x 10 4TCID50 / ml), and incubated at 37°C for 1 hour. An equal volume of PBS buffer (pH 7.2, 10 mM) was used as a virus control instead of the antibody diluent. An equal volume of DMEM medium containing 10% fetal bovine serum was used as a cell control instead of the test virus solution.

[0075] 3. After step 2 was completed, the cell culture plate was taken, and 100 microliters of hACE2-hela cell suspension (the solvent for preparing the cell suspension was DMEM medium containing 10% fetal bovine serum, and the concentration of hACE2-hela cells in the cell suspension was 2 x 10 5 cells / ml) was inoculated into each well, and incubated at 37°C for 64 hours.

[0076] 4. After step 3 was completed, the cell culture plate was taken, and the supernatant was aspirated, and 150 microliters of lysis solution (Microglasis Biotechnology, item number T003, according to the instructions) was added to each well, and incubated at 37°C for 5 minutes.

[0077] 5. After step 4 was completed, the cell culture plate was taken, and luciferase activity was detected.

[0078] Multiple replicates were set for each treatment.

[0079] Neutralization activity (%) = [1 - (fluorescence intensity of the test group - fluorescence intensity of the cell control) / (fluorescence intensity of the virus control - fluorescence intensity of the cell control)] x 100%.

[0080] The neutralization activity results are shown in Figure 1 . Figure 1 Neutralization activity (y-axis) and antibody concentration (x-axis) are shown in the figure. Antibody concentration refers to the concentration of the antibody in the mixture of 100 microliters of antibody diluent and 50 microliters of test virus solution in step 2.

[0081] The Prism 5 software was used to calculate the antibody concentration at which the neutralization activity was 50%, i.e., the IC50 value of the antibody.

[0082] The IC50 values (in ng / ml) of the P2-1B1 antibody for 12 novel coronavirus strains are shown in Table 1.

[0083] Table 1

[0084]

[0085]

[0086] The application has been described in detail. For those skilled in the art, the application can be implemented in a wider range under the same parameters, concentrations and conditions without departing from the spirit and scope of the application and without unnecessary experiments. Although the application gives a specific example, it should be understood that the application can be further improved. In summary, according to the principle of the application, the application intends to include any change, use or improvement of the application, including changes made by conventional techniques known in the art, which deviates from the range disclosed in the application. Some basic features can be applied within the scope of the following attached claims.

Claims

1. An IgG antibody against the spike protein of SARS-CoV-2, consisting of a light chain and a heavy chain; the CDR1, CDR2, and CDR3 in the heavy chain variable region of the heavy chain are shown, respectively, at positions 26-33, 51-58, and 97-114 in SEQ ID NO: 1; the CDR1, CDR2, and CDR3 in the light chain variable region of the light chain are shown, respectively, at positions 27-38, 56-58, and 95-103 in SEQ ID NO:

4.

2. The IgG antibody according to claim 1, wherein: The heavy chain variable region is shown in SEQ ID NO: 1; The light chain variable region is shown in SEQ ID NO:

4.

3. The IgG antibody according to claim 2, wherein: The heavy chain is (a) or (b) as follows: (a) the protein shown at positions 20-474 of SEQ ID NO: 2; (b) the protein shown in SEQ ID NO: 2; The light chain is (c) or (d) as follows: (c) the protein shown at positions 20 to 239 of SEQ ID NO: 5; (d) the protein shown by SEQ ID NO:

5.

4. A gene encoding the IgG antibody according to any one of claims 1 to 3.

5. Use of the IgG antibody according to claim 1, 2 or 3 in the preparation of a drug for inhibiting the new coronavirus; the new coronavirus is a new coronavirus D614G mutant strain, a new coronavirus Alpha strain, a new coronavirus Beta strain, a new coronavirus Gamma strain, a new coronavirus Delta strain, a new coronavirus Delta plus strain, a new coronavirus Mu strain, a new coronavirus Omicron BA.1 strain, a new coronavirus Omicron BA.2.12.1 strain, a new coronavirus Omicron BA.2.75 strain or a new coronavirus Omicron BA.3 strain.

6. A drug for inhibiting the new coronavirus, the active ingredient of which is the IgG antibody according to claim 1, 2 or 3.

7. Use of the IgG antibody according to claim 1, 2 or 3 in the preparation of a medicament for neutralizing the new coronavirus; the new coronavirus is a new coronavirus D614G mutant strain, a new coronavirus Alpha strain, a new coronavirus Beta strain, a new coronavirus Gamma strain, a new coronavirus Delta strain, a new coronavirus Delta plus strain, a new coronavirus Mu strain, a new coronavirus Omicron BA.1 strain, a new coronavirus Omicron BA.2.12.1 strain, a new coronavirus Omicron BA.2.75 strain or a new coronavirus Omicron BA.3 strain.

8. A drug for neutralizing the new coronavirus, the active ingredient of which is the IgG antibody according to claim 1, 2 or 3.

9. Use of the IgG antibody according to claim 1, 2 or 3 in the preparation of a medicament for preventing and / or treating novel coronavirus infection; the novel coronavirus is a novel coronavirus D614G mutant strain, a novel coronavirus Alpha strain, a novel coronavirus Beta strain, a novel coronavirus Gamma strain, a novel coronavirus Delta strain, a novel coronavirus Delta plus strain, a novel coronavirus Mu strain, a novel coronavirus Omicron BA.1 strain, a novel coronavirus Omicron BA.2.12.1 strain, a novel coronavirus Omicron BA.2.75 strain or a novel coronavirus Omicron BA.3 strain.

10. A drug for preventing and / or treating novel coronavirus infection, the active ingredient of which is the IgG antibody according to claim 1, 2 or 3.

Images